Role of Cholinergic Signaling in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 139 of the 141 references it cites were found in a registry or an index.
Abstract
Acetylcholine, a neurotransmitter secreted by cholinergic neurons, is involved in signal transduction related to memory and learning ability. Alzheimer’s disease (AD), a progressive and commonly diagnosed neurodegenerative disease, is characterized by memory and cognitive decline and behavioral disorders. The pathogenesis of AD is complex and remains unclear, being affected by various factors. The cholinergic hypothesis is the earliest theory about the pathogenesis of AD. Cholinergic atrophy and cognitive decline are accelerated in age-related neurodegenerative diseases such as AD. In addition, abnormal central cholinergic changes can also induce abnormal phosphorylation of ttau protein, nerve cell inflammation, cell apoptosis, and other pathological phenomena, but the exact mechanism of action is still unclear. Due to the complex and unclear pathogenesis, effective methods to prevent and treat AD are unavailable, and research to explore novel therapeutic drugs is various and active in the world. This review summaries the role of cholinergic signaling and the correlation between the cholinergic signaling pathway with other risk factors in AD and provides the latest research about the efficient therapeutic drugs and treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second-generation AChEIs, including donepezil (4), rivastigmine (5), galantamine (6), are more selective. They exhibited fewer side effects or improved pharmacokinetic profiles, establishing them as first-line drugs for AD.98,400”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is a progressive neurodegenerative disorder and the leading cause of dementia among older adults, characterized by a gradual decline in cognitive function, memory loss, and behavioral changes, ultimately leading to complete dependence on caregivers [7].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these, neurons of the nucleus basalis of Meynert (NBM) are particularly vulnerable, and their degeneration leads to profound reductions in choline acetyltransferase (ChAT) activity within projection areas such as the cerebral cortex and hippocampus, regions essential for learning, memory, and attention [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This hypothesis suggests that a reduction in the synthesis and release of ACh impairs its physiological functions, which are critical for learning, memory, and other cognitive processes.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“The cholinergic hypothesis, one of the earliest and most influential theories of AD, proposed that the characteristic cognitive deficits of the disorder arise primarily from degeneration of cholinergic neurons in the basal forebrain [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Hafez, H. S., Ghareeb, D. A., Saleh, S. R., Abady, M. M., Demellawy, M. E., Hussien, H. M., & Abdel-Monem, N. M. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4690-x · Cited by 85
RetractedSemwal, B. C., & Garabadu, D. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08615-1 · Cited by 9 · cited 2×
“Aβ can induce mitochondrial toxicity in the brain, resulting in cognitive dysfunction [5].”
BackgroundRetractedNEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311 · cited 1×
“According to clinical data in recent years, the brains of patients with AD show severe neurodegeneration and reduction of cholinergic neurons and a severe deficiency of Ach; acetylcholine transferase activity is significantly decreased, which further illustrates the damage to the cholinergic system in patients with AD…”
BackgroundEfficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Román, G. C., Jackson, R. E., Gadhia, R., Román, A. N., & Reis, J. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.08.005 · Cited by 421
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312 · cited 1×
“AD is a major cause of dementia which is a common disease among the elderly, starting with an irreversible decline in episodic memory and then a more general decline in overall cognitive ability [2,3].”
BackgroundLiu, Y., Zhang, Y., Zheng, X., Fang, T., Yang, X., Luo, X., Guo, A., Newell, K. A., Huang, X.-F., & Yu, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1141-5 · Cited by 285 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
BackgroundLuo, H., Xiang, Y., Qu, X., Liu, H., Liu, C., Li, G., Han, L., & Qin, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00395 · Cited by 264 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
Background
Research works printed but not linked: 1
- Yu, 2019, Protective roles of isoastilbin against Alzheimer’s disease via Nrf2mediated antioxidation and antiapoptosis, Int. J. Mol. Med., 43, 1406
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“98 These cell bodies of neurons are predominantly located in the medial septal nucleus (MSN), diagonal band of broca (DBB), NBM, and substantia innominata (SI).”
BackgroundTeleanu, R. I., Niculescu, A.-G., Roza, E., Vladâcenco, O., Grumezescu, A. M., & Teleanu, D. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115954 · Cited by 596
“Furthermore, as acetylcholine can regulate the normal cholinergic signal transduction (associated with learning and memory), its low levels in AD patients are no surprise, being manifested through damaged cholinergic signal transduction and cognitive impairment [11,104].”
BackgroundAdvance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Self-citationThe duality of amyloid-β: its role in normal and Alzheimer’s disease states
Azargoonjahromi, A. (2024) · Molecular Brain · doi:10.1186/s13041-024-01118-1 · Cited by 190
Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses
(2024) · aging and disease · doi:10.14336/ad.2023.0608 · Cited by 183
“It is important to recognize that AD not only inflicts irreversible and severe damage to the quality of life and mental well-being of patients, but also imposes significant economic and medical burdens on their families and society as a whole [234].”
BackgroundMuscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic
Yohn, S. E., Weiden, P. J., Felder, C. C., & Stahl, S. M. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.09.006 · Cited by 118
Aderinto, N., Olatunji, G. D., Muili, A. O., Ashinze, P. T., Faturoti, O., Ajagbe͓, A. O., Ukoaka, B. M., & Aboderin, G. (2023) · Medicine · doi:10.1097/md.0000000000035557 · Cited by 114
“[47] IRs in regions like the hippocampus and frontal cortex impact memory and neurotransmitter regulation.”
BackgroundAlzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 116
“Cholinergic neurons, particularly in the basal forebrain, play critical roles in memory, attention, and learning (Whitehouse et al., 1982) and degeneration of ACh-producing neurons in AD patients affects neuronal communication, resulting in memory de fi cits (Hasselmo, 2006; Chen et al., 2022).”
BackgroundMoussa, N., & Dayoub, N. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101729 · Cited by 102
“Acetylcholine (ACh) is a neurotransmmiter that plays a vital role in many aspects of brain function such as learning and memory (Chen et al., 2022; Liu et al., 2017), Ach is synthesized at nerve terminals from choline (Ch) and acetyl coenzyme A (Acetyl-CoA) by the action of the enzyme choline…”
Insulin resistance as the molecular link between diabetes and Alzheimer's disease
Abdalla, M. M. I. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i7.1430 · Cited by 88
Park, J. S., Rehman, I. U., Choe, K., Ahmad, R., Lee, H. J., & Kim, M. O. (2023) · Nutrients · doi:10.3390/nu15133059 · Cited by 86
“Furthermore, other factors such as abnormalities in cholinergic neurons, inflammatory cascades, and oxidative stress (OS) are contributing factors to the initiation and propagation of AD pathology [5].”
BackgroundCellular and organismal function of choline metabolism
Kenny, T. C., Scharenberg, S. G., Abu-Remaileh, M., & Birsoy, K. (2025) · Nature Metabolism · doi:10.1038/s42255-024-01203-8 · Cited by 82
“This is not surprising given the body of research that highlights the importance of the cholinergic neurotransmission in memory, learning and, ultimately, in the development of AD pathology 231,232 .”
Metabolic and Cellular Compartments of Acetyl-CoA in the Healthy and Diseased Brain
Jankowska-Kulawy, A., Klimaszewska‐Łata, J., Gul‐Hinc, S., Ronowska, A., & Szutowicz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710073 · Cited by 75
“These findings support the claim that several mechanisms generating acetyl-CoA deficits may take part in the preferential loss of cholinergic neurotransmission in the brains of AD patients and AD-Tg animals [81].”
BackgroundAlkhalifa, A. E., Mokhlf, A. A., Ali, H., Al-Ghraiybah, N. F., & Syropoulou, V. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15090437 · Cited by 77
“Skiing and the use of snow groomers causes soil compaction and degradation of vegetation cover [10, 12–15, 17, 19–21]. cerebral microhemorrhages (small red-brown foci at the gray–white junction) siderosis (thin cortical rim), typically visualized as hypointense lesions on T2/SWI , D ) is shown as…”
Grabowska, W. A., Bijak, M., Szelenberger, R., Gorniak, L., Podogrocki, M., Harmata, P., & Cichoń, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178726 · Cited by 73
“Disruption of this tightly regulated system, as seen in Alzheimer’s disease (AD) and other neurodegenerative disorders, leads to impaired cholinergic signalling, cognitive decline, and progressive neuronal dysfunction [3].”
Pathophysiology of Alzheimer’s Disease
Yarns, B. C., Holiday, K. A., Carlson, D. M., Cosgrove, C. K., & Melrose, R. J. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.07.003 · Cited by 68
Demir, Y., Şenol, H., Uluçay, O., Ateşoğlu, Ş., & Tokalı, F. S. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108683 · Cited by 67
Zeki, N. M., & Mustafa, Y. F. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.137601 · Cited by 64
Nagori, K., Nakhate, K. T., Yadav, K., Ajazuddin, & Pradhan, M. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3040053 · Cited by 61
Khedraoui, M., Abchır, O., Nour, H., Yamari, I., Errougui, A., Samadi, A., & Chtita, S. (2024) · Pharmaceuticals · doi:10.3390/ph17070830 · Cited by 60
“This theory holds that AD patients suffer from a decrease in cholinergic neurons [15], which leads to a decrease in ACh.”
BackgroundNagayach, A., Bhaskar, R., Ghosh, S., Singh, K. K., Han, S. S., & Sinha, J. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102450 · Cited by 58
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56
“AD is a progressive neurodegenerative disorder and the leading cause of dementia among older adults, characterized by a gradual decline in cognitive function, memory loss, and behavioral changes, ultimately leading to complete dependence on caregivers [7].”
BackgroundInsight into the emerging and common experimental in-vivo models of Alzheimer’s disease
Dhapola, R., Kumari, S., Sharma, P., & HariKrishnaReddy, D. (2023) · Laboratory Animal Research · doi:10.1186/s42826-023-00184-1 · Cited by 56
“It has been seen that there is increase in the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) and decrease in the activity of choline-acetyltransferase (ChAT) [120].”
BackgroundAnnulated Heterocyclic[g]Coumarin Composites: Synthetic Approaches and Bioactive Profiling
Zeki, N. M., & Mustafa, Y. F. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202301855 · Cited by 56
Qian, Q., Pu, Q., Li, L., Wu, J., Cheng, G., Cheng, Y., Wang, X., & Wang, H. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.137306 · Cited by 56
Wang, Y., Xue, Y., Zhao, Q., Wang, S., Sun, J. L., & Yang, X. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03290 · Cited by 56
Newer Therapeutic Approaches in Treating Alzheimer’s Disease: A Comprehensive Review
Sree, R. R., Kalyan, M., Anand, N., Mani, S., Gorantla, V. R., Sakharkar, M. K., Song, B., & Chidambaram, S. B. (2025) · ACS Omega · doi:10.1021/acsomega.4c05527 · Cited by 56
Fołta, J., Rzepka, Z., & Wrześniok, D. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115177 · Cited by 56
Prodrug Approach as a Strategy to Enhance Drug Permeability
de Souza, M. M., Gini, A. L. R., Moura, J. A., Scarim, C. B., Chin, C. M., & dos Santos, J. L. (2025) · Pharmaceuticals · doi:10.3390/ph18030297 · Cited by 55
“…decarboxylase (AADC) quickly metabolizes it and only 30% of the initial dose reaches systemic circulation avoid pre-systemic metabolism, levodopa is taken in combination with an AADC inhibitor, which is either benserazide or carbidopa; in this manner, oral bioavailability is nearly tripled [172].”
Ni, H., Liu, M., Cao, M., Zhang, L., Zhao, Y., Yi, L., Li, Y., Liu, L., Wang, P., Du, Q., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116190 · Cited by 52
Abbas, K., Mustafa, M., Alam, M., Habib, S., Ahmad, W., Adnan, M., Hassan, M. I., & Usmani, N. (2025) · Neurogenetics · doi:10.1007/s10048-025-00821-y · Cited by 51
Zang, W.-B., Wei, H., Zhang, W., Ma, W., Li, J., & Yao, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116070 · Cited by 50
Natural linear coumarin-heterocyclic conjugates: A review of their roles in phytotherapy
Zeki, N. M., & Mustafa, Y. F. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.105929 · Cited by 50
New Possibilities in the Therapeutic Approach to Alzheimer’s Disease
Doroszkiewicz, J., & Mroczko, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168902 · Cited by 50
“These actions are conducted by basal forebrain cholinergic neurons (BFCN), which are less present in AD patients because of neuron degeneration [26].”
BackgroundApplication of curcumin nanoformulations in Alzheimer’s disease: prevention, diagnosis and treatment
Lv, H., Wang, Y., Yang, X., Ling, G., & Zhang, P. (2022) · Nutritional Neuroscience · doi:10.1080/1028415x.2022.2084550 · Cited by 49
“central cholinergic changes can also cause pathological phenomena such as abnormal phosphorylation of tau protein, nerve cell inflammation and cell apoptosis [14].”
BackgroundNeurotransmitters in Type 2 Diabetes and the Control of Systemic and Central Energy Balance
Al-Sayyar, A., Hammad, M. M., Williams, M. R., Al‐Onaizi, M., Abubaker, J. A., & Alzaïd, F. (2023) · Metabolites · doi:10.3390/metabo13030384 · Cited by 48
“Acetyl Choline Acetylcholine (Ach) Cognition, learning, emory, modulation of electrical, and mechanical functions of the heart [51,68]”
BackgroundShi, M., Guo, Q., Xiao, Z., Sarengaowa, Xiao, Y., & Feng, K. (2024) · Foods · doi:10.3390/foods13131978 · Cited by 47
“The The product is presented in irregular strips or fine shreds [11]. product is presented in irregular strips or fi ne shreds 11.”
BackgroundMoawad, M. H. E. D., Serag, I., Alkhawaldeh, I. M., Abbas, A., Sharaf, A., Alsalah, S., Sadeq, M. A., Shalaby, M. M. M., Hefnawy, M. T., Abouzid, M., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04468-y · Cited by 46
Singh, D. D., Shati, A. A., Alfaifi, M. Y., Elbehairi, S. E. I., Han, I., Choi, E. H., & Yadav, D. K. (2022) · Cells · doi:10.3390/cells11233767 · Cited by 46
Asim, A., Jastrzębski, M. K., & Kaczor, A. A. (2025) · Molecules · doi:10.3390/molecules30142975 · Cited by 46
“One major area of research is improving cholinergic neurotransmission, which includes developing AChE inhibitors such as donepezil and rivastigmine to increase acetylcholine levels and slow down cognitive aging [96].”
Entorhinal cortex–hippocampal circuit connectivity in health and disease
Hernández‐Frausto, M., & Vivar, C. (2024) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2024.1448791 · Cited by 44
“…of the first theories linked to AD because MS and cholinergic neurons are particularly vulnerable to tau aggregates and neurodegeneration, both of them influencing the entorhinal–hippocampal processing as we discussed previously (Chen Z. R. et al., 2022; Igarashi, 2023; Salimi-Nezhad et al., 2023).”
MethodCostanzo, M., Cutrona, C., Leodori, G., Malimpensa, L., D’Antonio, F., Conte, A., & Belvisi, D. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01607-4 · Cited by 44
Gościniak, A., Stasiłowicz-Krzemień, A., Szeląg, M., Pawlak, J., Skiera, I., Kwiatkowska, H., Nowak, N., Bernady, K., Trzaskoma, P., Zimak-Krótkopad, O., et al. (2025) · Nutrients · doi:10.3390/nu17111939 · Cited by 44
Hein, Z. M., Karikalan, B., Gopalakrishna, P. K., Dhevi, K., Alkatiri, A., Hussan, F., Mohd Moklas, M. A., Jagadeesan, S., Che Ramli, M. D., Che Mohd Nassir, C. M. N., et al. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05602-0 · Cited by 43
Jia, W., Wang, H., Li, C., Shi, J., Yong, F., & Jia, H. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04969-3 · Cited by 42
“Deficiencies of vitamin B1 can result in heart failure and serious neurologic disorders such as paralysis, ataxia, confusion, and delirium [13, 33, 34].”
BackgroundJoshi, N. J., & Alavala, R. R. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101500 · Cited by 41
Islam, M. T., Aktaruzzaman, M., Saif, A., Hasan, A. R., Sourov, M. M. H., Sikdar, B., Rehman, S., Tabassum, A., Abeed-Ul-Haque, S., Sakib, M. H., et al. (2024) · RSC Advances · doi:10.1039/d4ra05073h · Cited by 41
Alayba, A. M., Senan, E. M., & Alshudukhi, J. S. (2024) · Scientific Reports · doi:10.1038/s41598-024-82544-y · Cited by 41
Bridging the brain and gut: neuroimmune mechanisms of neuroinflammation and therapeutic insights
Müller, L., & Benedetto, S. D. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1590002 · Cited by 41
Shoukat, S., Zia, M. A., Uzair, M., Attia, K. A., Abushady, A. M., Fiaz, S., Ali, S., Yang, S. H., & Ali, G. M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21161 · Cited by 39
Self-citationJain, S. K., Stevens, C. M., Margret, J. J., & Levine, S. N. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0245 · Cited by 38
“ACH, a neurotransmitter released by cholinergic neurons, is involved in cognition, learning, memory, and the suppression of inflammation (Chen et al., 2022).”
Kaur, K., Kulkarni, Y. A., & Wairkar, S. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148905 · Cited by 38
Kamath, A. P., Nayak, P. G., John, J., Mutalik, S., Balaraman, A. K., & Nandakumar, K. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110096 · Cited by 37
Recent Advances in Medicinal Chemistry of Memantine Against Alzheimer's Disease
Singh, Y. P., & Kumar, H. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14638 · Cited by 38
“The cholinergic pathways in the CNS are compromised in AD, leading to a cholinergic deficit that contributes to cognitive impairment in patients (Chen et al. 2022).”
Khaleghi-Mehr, M., Delshad, A.-A., Shafie-Damavandi, S., & Roghani, M. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01170-1 · Cited by 37
Carotenoid Supplementation for Alleviating the Symptoms of Alzheimer’s Disease
Flieger, J., Forma, A., Flieger, W., Flieger, M., Gawlik, P. J., Dzierżyński, E., Maciejewski, R., Teresiński, G., & Baj, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168982 · Cited by 37
“Memory and learning processes involve serotonin (5-HT) and cholinergic neurons, which synthesize acetylcholine (ACh) [19], especially in the hippocampus and cortical area [20–23].”
BackgroundAlzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 37
“This turns into AD-related mechanisms, such as neuroinflammation [52].”
Joo, L., Shim, W. H., Suh, C. H., Lim, S. J., Heo, H., Kim, W. S., Hong, E., Lee, D., Sung, J., Lim, J.-S., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0274562 · Cited by 35
Sugandhi, V. V., Gadhave, D. G., Ugale, A. R., Kulkarni, N. N., Nangare, S., Patil, H. P., Rath, S., Saxena, R., Lavate, A., Patel, A. T., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102775 · Cited by 35
Ertaş, A., Yiğitkan, S., & Orhan, İ. E. (2023) · Pharmaceuticals · doi:10.3390/ph16020171 · Cited by 35
The anterior olfactory nucleus revisited – An emerging role for neuropathological conditions?
Brunert, D., Quintela, R. M., & Rothermel, M. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102486 · Cited by 35
“, 2019) while the cholinergic theory locates the cause of AD in a dysfunctional basal forebrain cholinergic system (Chen et al., 2022).”
BackgroundThe integrated stress response in brain diseases: A double-edged sword for proteostasis and synapses
Lockshin, E. R., & Calakos, N. (2024) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2024.102886 · Cited by 34
“Notably, the cholinergic system is a focal point in AD research due to its role in cognition [64].”
BackgroundExploring Alzheimer's disease treatment: Established therapies and novel strategies for future care
Soni, U., Singh, K., Jain, D., & Pujari, R. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177520 · Cited by 33
Shin, Y. K., & Seol, G. H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1233977 · Cited by 33
Zhang, C., Guo, X., Wang, Y., Zhang, S., & Wang, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02441-4 · Cited by 33
“Dysregulated nAChR expression is implicated in cancer, neurodegenerative diseases, chronic inflammation, and autoimmunity [4, 50, 55–63].”
Benwood, C., Walters-Shumka, J. P., Scheck, K., & Willerth, S. M. (2023) · Bioelectronic Medicine · doi:10.1186/s42234-023-00112-7 · Cited by 32
“As well, ACh-deficiency in AD patients has shown to lead to a decline in cognitive and behavioural function so evaluating the release of ACh could lead to important insights in understanding the progression of AD (Chen et al. 2022; Crompton et al. 2013).”
BackgroundInfluentialBalakrishnan, R., Jannat, K., & Choi, D. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103105 · Cited by 32
“Cholinergic neurons synthesize acetylcholine (ACh), which plays a crucial role in learning and memory [17].”
BackgroundAlcohol, HMGB1, and Innate Immune Signaling in the Brain
Crews, F. T., Coleman, L. G., Macht, V. A., & Vetreno, R. P. (2024) · Alcohol research · doi:10.35946/arcr.v44.1.04 · Cited by 31
Farkas, S., Szabó, A., Török, B., Sólyomvári, C., Fazekas, C. L., Bánrévi, K., Correia, P., Chaves, T., & Zelena, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.985424 · Cited by 31
“3 Morris water maze test The latencies to reach the platform showed a significant improvement in time during the learning phase, independently from genotypes or surgery [F(4,132) = 43.”
BackgroundFunctional connectivity changes in mild cognitive impairment: A meta-analysis of M/EEG studies
Buzi, G., Fornari, C., Perinelli, A., & Mazza, V. (2023) · Clinical Neurophysiology · doi:10.1016/j.clinph.2023.10.011 · Cited by 31
Alzheimer disease: Amyloid peptide controversies and challenges of anti-Aβ immunotherapy
Almohmadi, N. H., Al-Kuraishy, H. M., Albuhadily, A. K., Al-Gareeb, A. I., Abdelaziz, A. M., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103639 · Cited by 30
“5,19 Therefore, acetylcholinesterase inhibitors such as rivastigmine, galantamine, and donepezil have been approved for the management of cognitive impairment in patients with AD.”
Han, J., Zhang, X., Kang, L., & Guan, J. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03443-1 · Cited by 29
The Selectivity of Butyrylcholinesterase Inhibitors Revisited
Gambardella, M. D., Wang, Y., & Pang, J. (2025) · Molecules · doi:10.3390/molecules30214201 · Cited by 29
“Memantine is a therapeutic primarily used to treat moderate to severe AD due to its inhibition of N-methyl D-aspartate (NMDA) receptors in the central nervous system (CNS) [11].”
Maria, C., & Rauter, A. P. (2023) · Carbohydrate Research · doi:10.1016/j.carres.2023.108889 · Cited by 29
Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Neurodegeneration
Taheri, M., Roghani, M., & Sedaghat, R. (2024) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-024-01502-4 · Cited by 29
“In addition, abnormal changes of brain cholinergic system can provoke tau phosphorylation, neuroinflammation, and apoptosis (Chen et al. 2022).”
BackgroundCamici, M., Duca, G. D., Brita, A. C., & Antinori, A. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1501949 · Cited by 28
“Adding another layer of complexity, a VN dysfunction and the consequent decline in cholinergic signaling can locally contribute to neurodegenerative processes (Chen et al., 2022).”
Thakur, A., Sharma, B., Parashar, A., Sharma, V., Kumar, A., & Mehta, V. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2192805 · Cited by 28
“…by the findings that treating rodents with cholinergic agonists resulted in marked improvement in memory and impaired cognitive performance and treatment with cholinergic antagonists resulted in deterioration of cognitive and memory functions (Ferreira-Vieira et al., 2016; Chen et al., 2022).”
BackgroundElgazar, A. A., El-Domany, R. A., Eldehna, W. M., & Badria, F. A.-E. (2023) · RSC Advances · doi:10.1039/d3ra04867e · Cited by 28
Noori, M., Dastyafteh, N., Safapoor, S., Ghomi, M. K., Tanideh, R., Zomorodian, K., Hamedifar, H., Dara, M., Zare, S., Irajie, C., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127392 · Cited by 28
Hamed, A. A., El‐Shiekh, R. A., Mohamed, O. G., Aboutabl, E. A., Fathy, F. I., Fawzy, G. A., Al‐Taweel, A. M., Elsayed, T. R., Tripathi, A., & Al-Karmalawy, A. A. (2023) · Molecules · doi:10.3390/molecules28062559 · Cited by 27
“In Alzheimer’s disease, the loss of cholinergic neurons and, consequently, the lack of acetylcholine (Ach) are directly linked to cognition decline [5].”
BackgroundEvidence of disturbed insulin signaling in animal models of Alzheimer’s disease
Alves, S. S., Servilha‐Menezes, G., Rossi, L., da Silva-Júnior, R. M. P., & Garcia‐Cairasco, N. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105326 · Cited by 27
Cáceres, C., Heusser, B., Garnham, A., & Moczko, E. (2023) · Cells · doi:10.3390/cells12232669 · Cited by 27
“Tests that specifically assess cholinergic function, such as the evaluation of attention and memory, may be helpful to support the hypothesis that AD is related to a deficiency in cholinergic neurotransmission [190].”
Ajibo, D. N., Orish, C. N., Ruggieri, F., Bocca, B., Battistini, B., Frazzoli, C., Orish, F. C., & Orisakwe, O. E. (2023) · Biological Trace Element Research · doi:10.1007/s12011-023-03965-w · Cited by 27
Han, X., Zhang, Y., Zhang, L., Zhang, L., & Wang, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117144 · Cited by 27
From Amyloid to Synaptic Dysfunction: Biomarker-Driven Insights into Alzheimer’s Disease
Agnello, L., Gambino, C. M., Ciaccio, A. M., Cacciabaudo, F., Massa, D., Masucci, A., Tamburello, M., Vassallo, R., Midiri, M., Scazzone, C., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080580 · Cited by 26
“Additionally, IGF-1 plays a crucial role in the CNS by supporting neuronal survival and modulating neuroinflammation [130].”
Neuropharmacology of synaptic plasticity: pathways to cognitive resilience in healthy aging
Goel, F., Singh, P., Nand, S., & Yadav, D. K. (2026) · 3 Biotech · doi:10.1007/s13205-025-04673-z · Cited by 26
Does Inflammation Play a Major Role in the Pathogenesis of Alzheimer's Disease?
Wiatrak, B., Jawień, P., Szeląg, A., & Jęśkowiak, I. (2023) · NeuroMolecular Medicine · doi:10.1007/s12017-023-08741-6 · Cited by 26
“, 2020), as well as the damage and loss of cholinergic neurons (Chen et al., 2022).”
BackgroundPourtaher, H., Mohammadi, Y., Hasaninejad, A., & Iraji, A. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00255a · Cited by 26
Samir, S. M., Hassan, H. M., Elmowafy, R., Nashar, E. M. E., Alghamdi, M. A., AlSheikh, M. H., Al-Zahrani, N. S., Alasiri, F. M., & Elhadidy, M. G. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1267675 · Cited by 26
Prabha, S., Choudhury, A., Islam, A., Thakur, S. C., & Hassan, M. I. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102680 · Cited by 26
Polyamine Dysregulation and Nucleolar Disruption in Alzheimer’s Disease
Brooks, W. H. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231184 · Cited by 25
Nrf2/Bach1 signaling axis: A promising multifaceted therapeutic strategy for Alzheimer's disease
Soni, P., Sharma, S. M., Pieper, A. A., Paul, B. D., & Thomas, B. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00586 · Cited by 25
Menthol and Its Derivatives: Exploring the Medical Application Potential
Zhang, J., Hu, Y., & Wang, Z. (2025) · Engineering in Life Sciences · doi:10.1002/elsc.70039 · Cited by 25
“Additionally, AD patients exhibit symptoms such as neuronal degeneration [51], synaptic damage [52], and reduced acetylcholine (ACh) neurotransmitter function [53], with ACh being a neurotransmitter closely associated with memory and cognition [54].”
Verma, A., Waiker, D. K., Singh, N. D., Roy, A., Singh, N., Saraf, P., Bhardwaj, B., Krishnamurthy, S., Trigun, S. K., & Shrivastava, S. K. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00653 · Cited by 25
Vicente, M. C., Addo-Osafo, K., & Vossel, K. A. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1277613 · Cited by 25
“In both DLB and AD, deficiencies in cholinergic activity are observable (115, 116).”
BackgroundMicroRNAs and synapse turnover in Alzheimer’s disease
Dalal, S., Ramirez-Gomez, J., Sharma, B., Devara, D., & Kumar, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102377 · Cited by 26
Bougea, A. M., Angelopoulou, E., Vasilopoulos, E., Gourzis, P., & Papageorgiou, S. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126542 · Cited by 25
“Acetylcholine (Ach) deficiency is considered to be one of key factors underlying cognitive impairment in AD [5].”
BackgroundYang, H., Zhang, T., Kim, M., Hur, H. J., Wu, X., Jang, D.-J., & Park, S. (2024) · Nutrients · doi:10.3390/nu16213751 · Cited by 25
Dong, S., Xia, J., Wang, F., Yang, L., Xing, S., Du, J., Zhang, T., & Li, Z. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116013 · Cited by 24
Jalil, S., Hussain, Z., Abid, S. M. A., Hameed, A., & Iqbal, J. (2024) · RSC Advances · doi:10.1039/d3ra05501a · Cited by 24
Metadata
- Authors
- Chen, Z.-R., Huang, J.-B., Yang, S.-L., & Hong, F.-F.
- Affiliations
- Nanchang University (CN)
- Experimental Center of Pathogen Biology, Nanchang University, Nanchang 330031, China
- Corresponding author
- Yang, Shu-Long
- Hong, Fen-Fang
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-03-10
- Volume
- 27
- Issue
- 6
- Pages
- 1816
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8949236
- OpenAlex
- W4220945110
- Cited by
- 922
- References
- 141
- Citations by year
- 2026: 256 · 2025: 347 · 2024: 202 · 2023: 87 · 2022: 29
- FWCI
- 22.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (82060661, 81660751, 81660151)
- Jiangxi Provincial Natural Science Foundation of China (20212BAB206092)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic neurotransmission, acetylcholine, cholinergic hypothesis, cognitive decline, tau phosphorylation, neuroinflammation, apoptosis, Alzheimer's disease pathogenesis, Alzheimer's disease therapeutics
- MeSH terms
- Acetylcholine, Alzheimer Disease, Humans, Signal Transduction, Cholinergic Agents, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.